Irinotekanijev Klorid Kabi

Irinotecan Hydrochloride Trihydrate, the active ingredient in Irinotekanijev Klorid Kabi, is a topoisomerase I inhibitor presented as an injectable solution for intravenous use. It is employed in the treatment of colorectal cancer, metastatic colorectal cancer, and other solid tumors in adult patients.

GNH USA supplies Irinotekanijev Klorid Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Irinotecan is a topoisomerase I inhibitor used in chemotherapy for gastrointestinal and other solid tumors.

Colorectal cancer: improves survival when combined with standard chemotherapy regimens. Metastatic colorectal cancer: used as part of combination therapy to reduce tumor burden. Other solid tumors: employed in selected cases where topoisomerase I inhibition is indicated.

Irinotecan may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting - Diarrhea, often severe - Neutropenia (low white blood cell count) - Fatigue and weakness - Alopecia (hair loss) - Mild liver enzyme elevations

Serious or Rare Side Effects: - Febrile neutropenia with risk of infection - Severe colitis or bowel perforation - Hepatic toxicity with jaundice - Anaphylactic or severe allergic reactions - Pulmonary toxicity (interstitial pneumonitis) - Cardiac arrhythmias in susceptible patients

Before initiating therapy, clinicians should assess patient-specific risk factors and monitor organ function.

Pregnancy: Category D – avoid use unless potential benefit justifies the risk. Breastfeeding: Not recommended; drug may be excreted in milk. Renal impairment: Use with caution and monitor renal function. Hepatic impairment: Adjust monitoring; dose may need modification. Concurrent myelosuppressive agents: Monitor for additive bone‑marrow suppression. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Irinotecan can interact with several medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole) – may increase exposure. - UGT1A1 inhibitors (e.g., atazanavir) – raise risk of neutropenia. - Live vaccines – heightened infection risk due to immunosuppression.

Moderate Interactions (Monitor Closely): - Other myelosuppressive chemotherapy agents – additive bone‑marrow toxicity. - High‑dose radiation therapy – may exacerbate tissue damage.